Which oral antipsychotic medications are typically used for schizophrenia before switching to Invega Sustenna (paliperidone palmitate) intramuscularly?

Oral Antipsychotics Typically Used Before Switching to Invega Sustenna

Before switching to Invega Sustenna (paliperidone palmitate), patients are most commonly treated with oral risperidone, oral paliperidone extended-release, or other oral antipsychotics including aripiprazole, olanzapine, and quetiapine. The FDA label explicitly recommends establishing tolerability with oral paliperidone or oral risperidone prior to initiating Invega Sustenna 1.

Algorithmic Approach to Pre-Switch Medications

First-Line Oral Antipsychotics

The most recent international guidelines 2 recommend that initial antipsychotic choice should be made collaboratively based on side-effect and efficacy profiles. Any oral antipsychotic can be used initially, with the understanding that:

• If first-line treatment fails after 4 weeks at therapeutic dose, switch to an alternative oral antipsychotic with a different pharmacodynamic profile 2
• For patients starting on a D2 partial agonist (like aripiprazole), second-line options include amisulpride, risperidone, paliperidone, or olanzapine 2

Specific Oral Medications Before Invega Sustenna

Real-world evidence demonstrates the following oral antipsychotics are commonly used before switching to paliperidone palmitate:

1. Oral risperidone (most common, as it's the parent compound) 3, 4
2. Oral paliperidone extended-release 3
3. Aripiprazole 3
4. Olanzapine 3
5. Quetiapine 3

Dose Equivalency When Switching

The FDA provides specific dose conversions from oral paliperidone to Invega Sustenna 1:

• Oral paliperidone 3 mg daily → Invega Sustenna 39-78 mg monthly
• Oral paliperidone 6 mg daily → Invega Sustenna 117 mg monthly
• Oral paliperidone 9 mg daily → Invega Sustenna 156 mg monthly
• Oral paliperidone 12 mg daily → Invega Sustenna 234 mg monthly

Critical Tolerability Testing Requirement

A crucial caveat: For patients who have never taken oral paliperidone or oral/injectable risperidone, tolerability MUST be established with oral formulations before initiating Invega Sustenna 1. This is an FDA-mandated safety requirement to avoid committing patients to a long-acting formulation if they cannot tolerate the medication.

Clinical Context for Switching

The APA guidelines 5 recommend long-acting injectable antipsychotics when:

• Patients prefer such treatment, OR
• Patients have a history of poor or uncertain adherence

Research shows that switching to paliperidone palmitate occurs in patients who are:

• Stable but symptomatic on oral therapy 3
• Non-acute but requiring improved adherence 3
• Previously treated with oral antipsychotics that were unsuccessful 3

Timing of the Switch

Previous oral antipsychotics can be gradually discontinued at the time of Invega Sustenna initiation 1. The standard initiation regimen is 234 mg deltoid on Day 1, followed by 156 mg deltoid on Day 8, regardless of which oral antipsychotic was used previously 1.

Research suggests starting Invega Sustenna 1 day after the last oral medication dose provides optimal benefit-risk compared to delayed starts 6. This minimizes both undertreatment and overlapping drug exposure.

Treatment-Resistant Cases

If two oral antipsychotics fail (each tried for ≥4 weeks at therapeutic dose with good adherence), clozapine should be considered before switching to any long-acting injectable 2. This is the evidence-based pathway for treatment-resistant schizophrenia, and Invega Sustenna would not be the appropriate next step in this scenario.